BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 31

• 

  COVID-19

  FDA’s own report shows no child deaths definitively caused by COVID vaccination

  Despite having no definitive data, Sen. Ron Johnson (R-WI) in a letter to health secretary Robert F. Kennedy, Jr. suggested there was a conscious effort by the Biden administration’s FDA to cover up the safety risks of COVID-19 vaccines.

  May 19, 2026

   · 

  3 min read

   · 

  Tristan Manalac
• Press Releases

  Avance Clinical to Showcase Oncology Leadership at ASCO Annual Meeting 2026

  May 19, 2026

   · 

  3 min read
• Press Releases

  EuroPCR 2026: Elixir Medical’s DynamX® Bioadaptor Demonstrates Significantly Lower Event Rates Than Drug-Eluting Stent

  May 19, 2026

   · 

  6 min read
• Press Releases

  Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors

  May 19, 2026

   · 

  7 min read
• Press Releases

  FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints

  May 19, 2026

   · 

  8 min read
• 

  Rare diseases

  BioMarin suffers another blow to rare disease portfolio in Phase 3 flop

  BioMarin’s investigational therapy failed to elicit clinical improvements in patients with ENPP1 deficiency, while also missing key secondary endpoints of rickets severity and growth.

  May 19, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress

  May 19, 2026

   · 

  10 min read
• Press Releases

  Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy

  May 19, 2026

   · 

  12 min read
• Press Releases

  Vanqua Bio to Present Positive Biomarker Data from Ongoing Phase 1b Study at Upcoming Medical Conferences

  May 19, 2026

   · 

  2 min read
• Press Releases

  EyePoint Announces Participation at Upcoming Investor Conferences - May 19, 2026

  May 19, 2026

   · 

  2 min read